Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

PHARMACOLOGICAL CHARACTERIZATION OF APROCITENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, ALONE AND IN COMBINATION WITH BLOCKERS OF THE RENIN ANGIOTENSIN SYSTEM, IN TWO MODELS OF EXPERIMENTAL HYPERTENSION.

Trensz F, Bortolamiol C, Kramberg M, Wanner D, Hadana H, Rey M, Strasser DS, Delahaye S, Hess P, Vezzali E, Mentzel U, Menard J, Clozel M, Iglarz M.

J Pharmacol Exp Ther. 2019 Jan 8. pii: jpet.118.253864. doi: 10.1124/jpet.118.253864. [Epub ahead of print]

2.

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.

Iglarz M, Landskroner K, Bauer Y, Vercauteren M, Rey M, Renault B, Studer R, Vezzali E, Freti D, Hadana H, Schl├Ąpfer M, Cattaneo C, Bortolamiol C, Weber E, Whitby BR, Delahaye S, Wanner D, Steiner P, Nayler O, Hess P, Clozel M.

J Cardiovasc Pharmacol. 2015 Nov;66(5):457-67. doi: 10.1097/FJC.0000000000000296.

3.

Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.

Iglarz M, Bossu A, Wanner D, Bortolamiol C, Rey M, Hess P, Clozel M.

Life Sci. 2014 Nov 24;118(2):333-9. doi: 10.1016/j.lfs.2014.02.018. Epub 2014 Feb 26.

Supplemental Content

Loading ...
Support Center